Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors

NCT03553108 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03553108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03553108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomised, Open-label, 4-Period Crossover Study to Develop an In Vitro-In Vivo Correlation for Olaparib Tablets in Subjects With Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2018
Completion date
July 1, 2020
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor